Misonix

Misonix, a provider of minimally invasive therapeutic ultrasonic technologies, has been acquired by Bioventus. Misonix stockholders received either 1.6839 shares of Bioventus class A common stock or $28.00 in cash per share.

Bioventus will acquire Misonix in a cash-and-stock transaction valued at approximately $518 million, adding minimally invasive ultrasonic technologies and regenerative medicine products.

Misonix Inc. entered into a definitive agreement to acquire Solsys Medical LLC in an all-stock transaction valued at approximately $97 million, including assumption of $20 million in secured debt.

Misonix, Inc. has entered into a definitive agreement to acquire Solsys Medical, LLC, a regenerative medical company, in an all-stock transaction valued at approximately $97 million. The combined entity is expected to generate over $80 million in annual revenue for fiscal 2020.

Misonix has signed an $11 million licensing and exclusive manufacturing agreement with Hunan Xing Hang Rui Kang Bio-Technologies for the SonaStar ultrasonic aspiration product line in China, Hong Kong and Macau. Misonix will receive $5 million upfront plus royalties.

Misonix entered into a license and exclusive manufacturing agreement with Hunan Xing Hang Rui Kang Bio-Technologies Co., Ltd. for its SonaStar product line in China, Hong Kong and Macau, with payments totaling a minimum of $11 million.